Last reviewed · How we verify
Live attenuated Japanese encephalitis vaccine SA14-14-2
Live attenuated Japanese encephalitis vaccine SA14-14-2 is a Biologic drug developed by Indian Institute of Science. It is currently FDA-approved.
The live attenuated Japanese encephalitis vaccine SA14-14-2, developed by the Indian Institute of Science, is currently marketed and holds a position in the vaccine market for Japanese encephalitis. A key strength is its key composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Live attenuated Japanese encephalitis vaccine SA14-14-2 |
|---|---|
| Sponsor | Indian Institute of Science |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 (PHASE4)
- Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine (NA)
- Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Live attenuated Japanese encephalitis vaccine SA14-14-2 CI brief — competitive landscape report
- Live attenuated Japanese encephalitis vaccine SA14-14-2 updates RSS · CI watch RSS
- Indian Institute of Science portfolio CI